Treatment of disorders

• US 20060002930A1
• Filed: 04/15/2005
• Published: 01/05/2006
• Est. Priority Date: 04/16/2004
• Status: Abandoned Application

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Brunetta, Paul G., Sewell, Kathryn L.
• Application Number:
  US11/106,820
• Publication Number:
  US 20060002930A1
• Time in Patent Office: Days
• US Class Current: 424/144.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 51/1027 against receptors, cell-surface antigens or cell-surface determinants
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention concerns treatment of polychondritis or mononeuritis multiplex in a mammal with an effective amount of an antibody that binds to CD20, optionally also with another agent that treats such disorders in an effective amount.

Claims

1. A method of treating polychondritis or mononeuritis multiplex in a mammal comprising administering to the mammal an effective amount of an antibody that binds CD20.

2. The method of claim 1 wherein the antibody is not conjugated with another molecule.

3. The method of claim 1 wherein the antibody is conjugated with another molecule.

4. The method of claim 3 wherein the other molecule is a cytotoxic agent.

5. The method of claim 4 wherein the cytotoxic agent is a radioactive compound.

6. The method of claim 5 wherein the cytotoxic agent comprises Y2B8 or ¹³¹I-B1.

7. The method of claim 1 wherein the antibody comprises rituximab.

8. The method of claim 1 wherein the antibody comprises a humanized 2H7.

9. The method of claim 1 comprising administering a dose of about 20 mg/m² to about 250 mg/m² of the antibody to the mammal.

10. The method of claim 9 wherein the dose is about 50 mg/m² to about 200 mg/m².

11. The method of claim 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m² dose of the antibody in the subsequent dose exceeds the mg/m² dose of the antibody in the initial dose.

12. The method of claim 1 wherein the mammal is human.

13. The method of claim 1 wherein the antibody is administered intravenously.

14. The method of claim 1 wherein the antibody is administered subcutaneously.

15. The method of claim 1 further comprising administering to the mammal an effective amount of an immunosuppressive agent, anti-pain agent, or a chemotherapeutic agent.

16. The method of claim 1 wherein polychondritis is treated.

17. The method of claim 16 further comprising administering to the mammal an effective amount of a nonsteroidal anti-inflammatory drug, steroid, methotrexate, cyclophosphamide, dapsone, azathioprine, penicillamine, or cyclosporine.

18. The method of claim 1 wherein mononeuritis multiplex is treated.

19. The method of claim 18 further comprising administering to the mammal an effective amount of an anti-pain agent, steroid, methotrexate, cyclophosphamide, plasma exchange, intravenous immunoglobulin, cyclosporine, or mycophenolate mofetil.

20. An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody that binds CD20, and further comprising a package insert instructing the user of the composition to treat polychondritis or mononeuritis multiplex in a mammal.

21. The article of claim 20 further comprising a container comprising an agent other than the antibody for the treatment and further comprising instructions on treating the mammal with such agent.